Represented by a patent law team from the law firm Noerr, the generic drug manufacturer TAD Pharma GmbH, a member of the KRKA d.d. group of pharmaceutical companies, was successful in temporary injunction proceedings of enormous legal as well as economic significance against the U.S. group of pharmaceutical companies Gilead Sciences Inc. The Munich Regional Court I dismissed Gilead's petition for temporary injunctions against a total of seven manufacturers of generic drugs, including TAD Pharma. Gilead had claimed a violation of a supplementary protection certificate (SPC) regarding its pharmaceutical TRUVADA (case nos. 7 O 11152/17 to 7 O 11158/17). An appeal against the ruling is possible.